Announcements
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
- BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
- BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
More ▼
Key statistics
As of last trade BridgeBio Pharma Inc (2CL:MUN) traded at 25.94, -33.76% below its 52-week high of 39.16, set on Dec 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.94 |
---|---|
High | 25.94 |
Low | 25.94 |
Bid | 25.79 |
Offer | 26.05 |
Previous close | 27.29 |
Average volume | 12.67 |
---|---|
Shares outstanding | 187.13m |
Free float | 144.85m |
P/E (TTM) | -- |
Market cap | 5.19bn USD |
EPS (TTM) | -3.23 USD |
Data delayed at least 15 minutes, as of May 24 2024 07:09 BST.
More ▼